L2M-Reinventing Drug Discovery and Cell Therapy Discovery, Validation and Safety Testing

To improve how diseases are treated, our team has developed a single, versatile platform that supports rapid drug discovery, therapeutic safety testing, and evaluation of cell-based therapies. In the longer term, the same technology will enable the bioengineering of transplantable human organs. Our initial work targets the kidney, pancreas, and lung—organs central to major chronic diseases. Current testing systems for drugs and cell therapies are inefficient and often fail to predict human outcomes, leading to high attrition in clinical trials. Our platform generates living three-dimensional organs that reproduce the complexity of animal models while allowing direct observation and measurement in real time. This provides faster, more reliable results, reduces research costs, and accelerates the translation of new treatments from the laboratory to patients.

Faculty Supervisor:

Ian Rogers

Student:

Partner:

DMZ Ventures Inc

Discipline:

Business

Sector:

Professional, scientific and technical services

University:

University of Toronto

Program: